Bruker's Mass Spectrometry Breakthrough Maps Human Plasma Proteome at Proteoform Level
Event summary
- Bruker's timsTOF mass spectrometry detected 5,077 plasma protein groups and 179,049 distinct proteoforms in a draft atlas of the human plasma proteome.
- The study, led by Markus Ralser at Charité – Universitätsmedizin Berlin, revealed that canonical proteins may constitute less than half of total protein content in blood.
- The research combined intact protein fractionation with diaPASEF mass spectrometry to resolve proteoform diversity at an unprecedented scale.
- The draft atlas was published as a preprint on bioRxiv on September 28, 2026.
The big picture
Bruker's breakthrough underscores the growing importance of proteoform resolution in understanding complex biological systems. The study challenges conventional protein measurement methods and highlights the potential for more precise diagnostic and therapeutic tools. This advancement aligns with broader industry trends toward personalized medicine and multiomics approaches in biomedical research.
What we're watching
- Biomarker Development
- How the proteoform atlas will accelerate the discovery of more specific biomarkers for disease diagnosis and monitoring.
- Drug Targeting
- Whether the resolution of proteoform diversity will enable the development of more targeted and effective therapeutic interventions.
- Technological Adoption
- The pace at which Bruker's timsTOF mass spectrometry systems will be adopted for proteoform-specific research in academia and industry.
Related topics